The central risk is not that the science stops, but that commercialization stays narrow. If D-Wave cannot turn bookings, pilots, and system announcements into durable recurring usage before investors demand harder proof, the stock can derate even while technical progress continues. Secondary risks are
gate-model roadmap slippage, large-customer concentration, and losing workflow ownership to classical software or larger platform vendors.